Advertisement

Topics

Activated Dual Specificity Lymphocytes and Their Methods of Use

19:00 EST 31 Mar 2002 | NIH

While T-cell therapies can work in some patients, the use of these cells to treat cancer and viral diseases is often limited by the poor survival and proliferation of these cells in vivo. Cancer clinical trials have demonstrated that the transferred lymphocytes can recognize tumors in vitro, but human subjects often do not respond to infusion. Gene marking studies have demonstrated that the transferred cells often survive for only short periods of time in vivo, thus limiting their effectiveness.

The current invention relates to a method of using genetic modification to generate leukocytes with multiple specificities. To improve proliferation and activation of the transduced T cells, cell transfer is combined with stimulation using a second antigen. Thus, T cells are stimulated through their native T cell receptor, using a powerful immunogen, which facilitates expansion and activation. In experiments, mice receiving alloantigen stimulated cells rejected tumors while mice receiving the unstimulated cells did not reject the tumor cells. This technology represents a potential therapy for a wide variety of malignancies, and because of the genetic modification used, this therapy will be applicable to patients of any MHC type.

IC: 
NCI
NIH Ref. No.: 
E-323-2000/0
TAB No: 
TAB-597
Advantages: 
  • Genetic modification allows for infusion of T-cells with multiple specificities
  • Applicable to therapies for a wide variety of malignancies
Applications: 
  • Therapeutic treatment for cancer patients using genetically modified leukocytes
  • Personalized medicine for patients eligible for immunotherapy
Provider Technology ID: 
597
Updated On: 
Oct 23, 2017
Provider Classifications: 
Date Published: 
Monday, April 1, 2002
Patent Application: 
09/803,578
Publications: 
Patent Authority: 
US
Patent Number: 
7,723,111
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
LPM FIrst Name: 
Andrew
LPM Last Name: 
Burke
LPM Address: 
9609 Medical Center Drive, Room 1E-530 (MSC 9702)
LPM City: 
Rockville
Inv Is lead: 
LPM Zip: 
20850-9702
LPM State: 
MD
LPM Phone: 
240-276-5484
LPM Suffix: 
Ph.D.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-276-5504
DTDT Classification: 
Cancer
Therapeutics
Vaccines
Immunomodulators and Immunostimulants
Brochure - In-vivo Data
Cancer
Therapeutic (biologic)
Biomarker
In vivo data available (animal)
DTDT Description: 
Cancer
Cancer - Therapeutics
Cancer - Therapeutics: Vaccines
Cancer - Therapeutics: Immunomodulators and Immunostimulants
In-vivo Data
Cancer
Therapeutic (biologic)
Biomarker
In vivo data available (animal)
Pat Filing Date: 
2001-03-09
Patent Issue Date: 
2010-05-25
Additional Patents: 
European Patent No. 1379670 issued August 6, 2008
Application Term: 
Disease Area Term: 
Technology Term: 
Development Stage Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Researchers at the NCI seek licensing and/or co-development research collaborations for genetically modified leukocytes with multiple specificities.

E Number Only: 
E-323-2000
Inventor First Name: 
Patrick
Michael
Inventor Last Name: 
Hwu
Kershaw

Original Article: Activated Dual Specificity Lymphocytes and Their Methods of Use

NEXT ARTICLE

More From BioPortfolio on "Activated Dual Specificity Lymphocytes and Their Methods of Use"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...